Studies have demonstrated that TEAD4 mediated EMT of bladder cancer through PI3K/Akt pathway, indicating that TEAD4 could serve as an effective biomarker for prognosis prediction and a potential target for the treatment of metastatic bladder cancer [48]. This evidence concerns the gene AKT1 and urinary bladder cancer.